Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...
Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange ...
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
Shares of Cassava Sciences, Inc (NASDAQ:SAVA) dropped 11.5% in pre-open trade on Friday following the company's statement ...
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...
2h
Shares of Cassava Sciences, Inc. SAVA fell sharply in today's pre-market trading after the SEC charged the company, two ...
Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, ...
Cassava Sciences shares fell in premarket trading Friday after regulators said the company, along with two former executives, will pay more than $40 million to settle charges related to misleading ...
Fidelity slashed the amount certain customers can deposit into their cash-management accounts to $1,000 from $100,000, people familiar with the matter said. The Boston firm is also subjecting some ...
Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback